Actively Recruiting
Phase 3 Study Comparing Ivonescimab Plus FOLFOX Versus Bevacizumab Plus FOLFOX for First-line Treatment of Metastatic Colorectal Cancer
Led by Summit Therapeutics · Updated on 2026-11-04
600
Participants Needed
243
Research Sites
78 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a phase 3, randomized, double-blind study to evaluate the effectiveness of Ivonescimab combined with mFOLFOX6 versus Bevacizumab combined with mFOLFOX6 for the first-line treatment of metastatic colorectal cancer. The trial includes patients who have not previously received systemic therapy for metastatic disease and aims to compare these treatments in a controlled setting. Participants will be randomly assigned to one of two treatment groups Ivonescimab plus mFOLFOX6 or Bevacizumab plus mFOLFOX6. Both treatments are given by intravenous infusion every two weeks for up to eight cycles. After these initial treatment cycles, maintenance therapy with Ivonescimab or Bevacizumab combined with Leucovorin and 5-Fluorouracil will be administered every two weeks for up to two years. Throughout the study, participants will undergo regular assessments to monitor disease progression using standardized imaging criteria. Researchers will evaluate progression-free survival as the primary outcome over approximately 2.5 years, alongside secondary outcomes including overall survival, tumor response rate, duration of response, and adverse events over up to 4 years. Study-related care and follow-up will be conducted during this period to assess treatment effects and safety.
CONDITIONS
Brief Title
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Research Team
N
Ning Chang, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here